Cann Group Ltd
ASX:CAN
Net Margin
Cann Group Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Cann Group Ltd
ASX:CAN
|
9.1m AUD |
-307%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
723.1B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
404.4B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.4B CHF |
14%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
35%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
173B GBP |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
183.4B CHF |
25%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
207.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
138.1B USD |
13%
|
Cann Group Ltd
Glance View
Cann Group Ltd. operates research and development and cultivation facilities to grow medicinal cannabis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The firm has established research and cultivation facilities in Melbourne and is developing a cultivation facility near Mildura, Victoria. The company focuses on developing and supplying cannabis, cannabis resin and medicinal cannabis products into the Australian market. The firm has a cannabis research license and cannabis cultivation license. The cannabis cultivation license allows the Company to produce Australian grown material that can be prescribed for patient use. The company focuses on plant genetics, breeding, cultivation, extraction, analysis and production techniques to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Cann Group Ltd's most recent financial statements, the company has Net Margin of -307.4%.
You don't have any saved screeners yet